CGIX:NSD-Cancer Genetics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.64

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

0.27M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD173.59B 50.81 42.70
BNTX BioNTech SE

N/A

USD87.11B 19.76 15.10
REGN Regeneron Pharmaceuticals Inc

N/A

USD69.72B 11.77 9.07
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD48.85B 24.83 16.64
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD37.67B N/A N/A
SGEN Seagen Inc

N/A

USD28.42B 48.74 37.66
GMAB Genmab A/S

N/A

USD27.66B 70.01 8.47
RPRX Royalty Pharma plc

N/A

USD23.38B 31.17 12.50
ALNY Alnylam Pharmaceuticals Inc

N/A

USD22.62B N/A N/A

ETFs Containing CGIX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 67.51% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.51% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 5.69% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.69% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 165.14% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 165.14% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 469.13% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 469.13% 98% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,044.49% 2% F 2% F
Risk Adjusted Return 44.91% 71% C- 66% D
Market Capitalization 0.05B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.13 N/A N/A N/A N/A
Price / Cash Flow Ratio -9.92 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -68.71% N/A N/A N/A N/A
Return on Invested Capital -129.46% N/A N/A N/A N/A
Return on Assets -14.90% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.56 N/A N/A N/A N/A
Short Percent 6.91% N/A N/A N/A N/A
Beta 2.72 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.